Top

Published in:

01-09-2011 | Head and Neck Oncology

Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy

Authors: Chun-Ta Liao, MD, Chien-Yu Lin, MD, Kang-Hsing Fan, MD, Shiang-Fu Huang, MD, I-How Chen, MD, Chung-Jan Kang, MD, Hung-Ming Wang, MD, Shu-Hang Ng, MD, Chuen Hsueh, MD, Li-Yu Lee, MD, Chih-Hung Lin, MD, Tzu-Chen Yen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2011

Abstract

Background

The NCCN 2010 guidelines recommend the use of postoperative adjuvant radiotherapy (RT) for patients with pT3 oral cavity squamous cell carcinoma (OSCC). We sought to determine whether postoperative adjuvant RT improves outcomes in pT3N0 OSCC patients.

Methods

A total of 119 consecutive patients with pT3N0 disease were involved. A total of 42 patients received postoperative adjuvant RT, while the remaining 77 did not. The 5-year rates of control, distant metastasis, and survival were the main outcome measures.

Results

We found no differences in the risk profile of patients with and without postoperative adjuvant RT, the only exceptions being a higher frequency of tumor depth ≥10 mm (78.6% vs. 48.0%, P = .001) and close margins ≤4 mm (11.9 % vs. 2.7%, P = .043) in those treated by adjuvant RT. Tumor depth ≥10 mm was the only independent prognostic factor for 5-year local control, disease-free survival, and disease-specific survival in multivariable analysis. Tumor depth ≥13 mm was the only independent prognostic factor for the 5-year rate of distant metastases (16% [7 of 50] vs. 2% [1 of 67]). After stratification for tumor depth and adjuvant RT, patients with pT3N0 disease who received adjuvant RT did not show a survival advantage.

Conclusions

Tumor depth ≥10 mm was the only prognostic factor identified in patients with pT3N0 disease. Adjuvant RT did not improve outcomes in pT3N0 patients, regardless of tumor depth. Patients with pT3N0 and tumor depth ≥13 mm (43% of pT3N0) were at the highest risk for distant metastases.

Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Head and Neck Cancers, V. I. 2010. http://www.nccn.org/. Accessed 21 May 2010.

Shah JP, Gil Z. Current concepts in management of oral cancer-surgery. Oral Oncol. 2009;45:394–401.PubMedCrossRef

Ballonoff A, Chen C, Raben D. Current radiation therapy management issues in oral cavity cancer. Otolaryngol Clin North Am. 2006;39:365–80.PubMedCrossRef

Langendijk JA, de Jong MA, Leemans CR, de Bree R, Smeele LE, Doornaert P, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57:693–700.PubMedCrossRef

Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002;24:115–26.PubMedCrossRef

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Survival in squamous cell carcinoma of the oral cavity: differences between pT4N0 and other stage IVA categories. Cancer. 2007;110:564–71.PubMedCrossRef

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Does adjuvant radiation therapy improve outcome in pT1-3N0 oral cavity cancer with tumor-free margins and peripheral invasion? Int J Radiat Oncol Biol Phys. 2008;71:371–6.PubMedCrossRef

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors predictive of local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–22.PubMedCrossRef

10.

Brown JS, Blackburn TK, Woolgar JA, Lowe D, Errington RD, Vaughan ED, et al. A comparison of outcomes for patients with oral squamous cell carcinoma at intermediate risk of recurrence treated by surgery alone or with post-operative radiotherapy. Oral Oncol. 2007;43:764–73.PubMedCrossRef

11.

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.PubMedCrossRef

12.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.PubMedCrossRef

13.

Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.PubMedCrossRef

14.

Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol. 2006;24:2629–35.PubMedCrossRef

15.

Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathologic staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:429–35.PubMedCrossRef

16.

Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2004;17:5820–4.CrossRef

17.

Baghi M, Hambek M, May A, Radeloff A, Gstoettner W, Knecht R. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Anticancer Res. 2006;26:559–63.PubMed

18.

Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, et al. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009;27:4727–32.PubMedCrossRef

Title: Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy
Authors: Chun-Ta Liao, MD
Chien-Yu Lin, MD
Kang-Hsing Fan, MD
Shiang-Fu Huang, MD
I-How Chen, MD
Chung-Jan Kang, MD
Hung-Ming Wang, MD
Shu-Hang Ng, MD
Chuen Hsueh, MD
Li-Yu Lee, MD
Chih-Hung Lin, MD
Tzu-Chen Yen, MD, PhD
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 9/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1616-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2011

Can Lymph Node Ratio Take the Place of pN Categories in the UICC/AJCC TNM Classification System for Colorectal Cancer?

Surgical Caseload is an Important Determinant of Continent Urinary Diversion Rate at Radical Cystectomy: A Population-Based Study

American Board of Surgery Certificate in Complex General Surgical Oncology: A Reality

Towards More Effective Liver Allocation Criteria for Hepatocellular Carcinoma: Tumor Response to Locoregional Therapy

Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution

Nicotine Promotes Cell Migration Through Alpha7 Nicotinic Acetylcholine Receptor in Gastric Cancer Cells